Investing.com - Theravance Biopharma (NASDAQ: TBPH) reported first quarter EPS of $-0.24, $0.01 better than the analyst estimate of $-0.25. Revenue for the quarter came in at $14.5M versus the consensus estimate of $14.92M.
Theravance Biopharma's stock price closed at $9.58. It is up 10.50% in the last 3 months and down -15.31% in the last 12 months.
Theravance Biopharma saw 2 positive EPS revisions and 0 negative EPS revisions in the last 90 days. See Theravance Biopharma's stock price’s past reactions to earnings here.
According to InvestingPro, Theravance Biopharma's Financial Health score is "good performance".
Check out Theravance Biopharma's recent earnings performance, and Theravance Biopharma's financials here.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar